LeMaitre Vascular (LMAT) to Release Quarterly Earnings on Thursday

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) is projected to announce its Q1 2025 earnings results after the market closes on Thursday, May 1st. Analysts expect the company to announce earnings of $0.50 per share and revenue of $57.61 million for the quarter. LeMaitre Vascular has set its FY 2025 guidance at 2.150-2.320 EPS and its Q1 2025 guidance at 0.480-0.530 EPS.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.49. The company had revenue of $55.81 million during the quarter, compared to analyst estimates of $55.99 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. On average, analysts expect LeMaitre Vascular to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

LeMaitre Vascular Stock Performance

LMAT stock traded up $1.06 during midday trading on Tuesday, reaching $92.60. The stock had a trading volume of 139,319 shares, compared to its average volume of 161,689. The stock has a market cap of $2.09 billion, a PE ratio of 50.60, a P/E/G ratio of 2.22 and a beta of 0.89. The firm has a fifty day simple moving average of $86.50 and a two-hundred day simple moving average of $93.45. LeMaitre Vascular has a 52-week low of $64.44 and a 52-week high of $109.58.

LeMaitre Vascular Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Shareholders of record on Thursday, March 13th were paid a dividend of $0.20 per share. The ex-dividend date was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.86%. This is a positive change from LeMaitre Vascular's previous quarterly dividend of $0.16. LeMaitre Vascular's dividend payout ratio (DPR) is presently 41.24%.

Analysts Set New Price Targets

LMAT has been the subject of a number of recent research reports. Wells Fargo & Company initiated coverage on LeMaitre Vascular in a research note on Thursday, February 13th. They set an "equal weight" rating and a $95.00 price objective for the company. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Lake Street Capital lifted their price objective on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Finally, Oppenheimer lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $98.14.

Insider Buying and Selling

In related news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.79% of the stock is currently owned by insiders.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.